Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04AAN
|
||||
| Former ID |
DAP000252
|
||||
| Drug Name |
Mesoridazine
|
||||
| Synonyms |
Calodal; Lidanar; Lidanil; Mesoridazina; Mesoridazinum; Serentil; Serentil Concentrate; Thioridazien thiomethyl sulfoxide; Thioridazine monosulfoxide analog; Thioridazine thiomethyl sulfoxide; TPS 23; Tps23; Lidanar (TN); Mesoridazina [INN-Spanish]; Mesoridazinum [INN-Latin]; NC-123; Serentil (TN); TPS-23; Mesoridazine (USAN/INN); Mesoridazine [USAN:BAN:INN]; T-2-SO; THD-2-SO; Thioridazine-2-sulfoxide; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Approved | [1], [2] | ||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Company |
Norvatis Phamaceuticals Corporation
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H26N2OS2
|
||||
| InChI |
InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
|
||||
| InChIKey |
SLVMESMUVMCQIY-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 5588-33-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9352, 447728, 614172, 4379956, 7979909, 8140528, 8152557, 10319751, 10527260, 11405940, 11467677, 11486174, 14927472, 17396840, 26756521, 29223187, 46506724, 47440446, 47440447, 47662489, 47885582, 48035319, 48035320, 48416224, 49699103, 50006596, 50111387, 50111388, 50704712, 57322129, 85209561, 85787941, 85788345, 92309158, 96099906, 103301322, 104022598, 104222090, 104305362, 124892406, 125672983, 129255022, 134337566, 134988360, 137248555, 139029518, 144203603, 144205571, 160964272, 163157019
|
||||
| SuperDrug ATC ID |
N05AC03
|
||||
| SuperDrug CAS ID |
cas=005588330
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016774. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7227). | ||||
| REF 3 | Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005Dec;315(3):1278-87. Epub 2005 Aug 31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.